Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Renshen Jianxin is a Traditional Chinese Medicine (TCM) capsule formulation developed by the Affiliated Hospital of Shandong University of Traditional Chinese Medicine for the treatment of stable coronary artery disease (CAD). The name 'Renshen' refers to *Panax ginseng*, a primary component known for its cardioprotective properties, while 'Jianxin' translates to 'strengthening the heart.' The drug is intended to improve myocardial function, enhance exercise tolerance, and alleviate clinical symptoms in patients with chronic stable angina or coronary heart disease. It has been evaluated in clinical trials both as a standalone therapy and as an adjunct to aerobic exercise interventions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Renshen Jianxin.